RE: Q&A30 Jul 2021 15:29
"Q78: Can you confirm if the manufacturing equipment that was provided by the DHSC if being utilized to the maximum to manufacture ODX related products or are we restricted to 1 million a week based on using our own equipment (ie are we not allowed to use the DHSC equipment until they have chosen a product to manufacture)
The UK Government equipment will be used to manufacture tests for the DHSC – not for the production of tests that we will sell to other third parties."
So whatever the % capacity is via the gov equipment, that currently idoing nothing.
Q73: How long will EUA take in America. GDR have been waiting over 18 months. Will this likely be a hurdle for ODX?
We aren’t providing guidance on the FDA EUA process as this isn’t a pre-determined fixed timescale or easy to predict.
Anyone on here telling you FDA approval is any day now is just feeding you unsubstantiated rubbish, CEO just made it clear they don't know and it isn't easy for them to predict. Some here find it very easy.
In answer to Q205.
The Mologic test was not chosen by the DHSC, and our VISITECT would need to complete self-test authorization before being available for the DHSC to consider.
The tone of that first part would indicate that the Mologic test is now totally dead in terms of its possibility of being the gov test.
Q29: Is Antibody Lateral Flow Test Visitect still existing product or was it dropped due to lack of commercial interest? Sometimes in your communication with shareholders company itself and Walbrook don’t even mention it anymore as a part of the product range.
With regards antibody test, we are focused on the UK-RTC product, initially this product was for the UK market and our Visitect for other markets, however as both tests are professional tests we didn’t want to compete against each other.
I'll leave it to the reader to determine where you heard it first that the tri-antibody test was dead (hint it was me).
Q89: Any updates on getting money from the antibody consortium for the order placed by the DHSC for the antibody test last year?
The outcome is dependent upon Abingdon Health’s discussions with DHSC and whilst there has been some progress made, it is difficult to give timeframes for payment at this time.
It's likely to be paid at some point, so that'll be extra into the revenue line at some stage.
Although asked about 10 different ways, the consistent reply was that they were not going to give current production levels, previous production levels, total production levels, amount of units in stockpile or margins. This is the same company that was happy to given an unconditional forward looking statement of"we'll deliver 2M lft per week in april"
I understand not revealing margins, that's far too much to give away to potential competitors, but for what is solely a manufacturing company not to give any historic figures of stuff manufactured is a bit weird.
Sign In
Follow the stocks
